Stocktoria
AtaiBeckley Inc. ATAI
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-06-18
AtaiBeckley Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | $4.1M | $308,000 |
| R&D expense | — | $900,000 |
| Operating income | -$644.1M | -$102.7M |
| Income tax | $298,000 | -$356,000 |
| Net income | -$660.0M | -$149.3M |
| EPS (diluted) | $-2.91 | $-0.93 |
| Operating cash flow | -$102.7M | -$82.4M |
| Free cash flow | -$103.6M | -$82.4M |
| Cash & equivalents | $85.3M | $17.5M |
| Total assets | $292.7M | $159.4M |
| Total liabilities | $70.7M | $42.8M |
| Shareholders' equity | $222.0M | $116.6M |
Source: SEC EDGAR filings · CIK 0002081043 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.